ElevateBio Scales Disruptive Cell and Gene Therapy Business Model with $525 Million Series C Financing
Summary
At ElevateBio, we can realize the full potential of cell and gene therapies, by re-envisioning the way these products are made, breaking down silos, leveraging powerful enabling technologies, and changing the mindset from simple manufacturing scale-up to conducting large scale biology. "ElevateBio’s business model maximizes the potential to capitalize on the convergence of technology and healthcare, creating an entirely new category in cell and gene therapy," said Karan Takhar. "The company is redefining the way cell and gene therapies are discovered, developed, and manufactured, bringing together cutting-edge scientific and digital technologies to enable a seismic shift in the field." Deep Nishar added, "We are proud to support ElevateBio’s world-class team to expand and advance its technology and manufacturing platforms to accelerate the production and development of tomorrow’s life-saving cell and gene therapies." The company has built an initial technology stack, including gene editing, induced pluripotent stem cells, and protein, viral, and cellular engineering.